• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成年呼吸系统疾病患者的免疫衰老、免疫健康与疫苗接种计划

Immunosenescence, Immune Fitness and Vaccination Schedule in the Adult Respiratory Patient.

作者信息

Villar-Álvarez Felipe, de la Rosa-Carrillo David, Fariñas-Guerrero Fernando, Jiménez-Ruiz Carlos A

机构信息

Pneumology Department, IIS Fundación Jiménez Díaz, CIBERES, Universidad Autónoma of Madrid, Madrid, Spain.

Pneumology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

出版信息

Open Respir Arch. 2022 May 16;4(3):100181. doi: 10.1016/j.opresp.2022.100181. eCollection 2022 Jul-Sep.

DOI:10.1016/j.opresp.2022.100181
PMID:37496575
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9109993/
Abstract

Immunosenescence is the gradual deterioration of the immune system caused by advancing age. It is associated with a reduced ability to respond to infections and develop long-term immune memory. It plays a key role in the development of respiratory diseases that are more common in older people, such as asthma, COPD, diffuse interstitial disease and respiratory infections in the elderly. We call immune fitness the establishment of lifestyle habits that can improve our immune capacity. We now know that good eating habits, good social relationships, not smoking, limiting alcohol consumption, exercising, controlling stress levels and establishing a proper vaccination programme can slow down the process of immunosenescence. Influenza and pneumococcal vaccines (PCV13 and PPSV23 conjugate) are well established in the adult vaccination schedule. The new pneumococcal vaccines PCV15 and PCV20 will help to extend protection against pneumococcal disease in adults. The vaccine against COVID-19 is currently the most useful tool to prevent the disease and reduce its pathogenicity. COPD patients and others with respiratory diseases may benefit from prevention of herpes zoster and through vaccination. Respiratory syncytial virus (RSV) vaccine may be another vaccine to be added to the schedule, pending the results of its studies.

摘要

免疫衰老指的是免疫系统因年龄增长而逐渐衰退的现象。它与应对感染及形成长期免疫记忆的能力下降有关。在老年人中更常见的呼吸道疾病,如哮喘、慢性阻塞性肺疾病(COPD)、弥漫性间质性疾病以及老年人的呼吸道感染等的发病过程中,免疫衰老起着关键作用。我们将能够提升免疫能力的生活方式习惯的养成称为免疫健康。我们现在知道,良好的饮食习惯、良好的社会关系、不吸烟、限制饮酒、锻炼、控制压力水平以及制定适当的疫苗接种计划,可以减缓免疫衰老的进程。流感疫苗和肺炎球菌疫苗(13价肺炎球菌结合疫苗和23价肺炎球菌多糖疫苗)在成人疫苗接种计划中已得到广泛应用。新型肺炎球菌疫苗15价肺炎球菌结合疫苗和20价肺炎球菌结合疫苗将有助于扩大对成人肺炎球菌疾病的防护范围。目前,新冠疫苗是预防该疾病并降低其致病性的最有效工具。慢性阻塞性肺疾病患者及其他呼吸道疾病患者可能会通过接种疫苗预防带状疱疹而受益。呼吸道合胞病毒(RSV)疫苗在研究结果出来之前,可能会成为疫苗接种计划中新增的另一种疫苗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89f1/10369615/5a0aa3479a37/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89f1/10369615/b37ebb57dcf0/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89f1/10369615/a424f7939a94/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89f1/10369615/578964985c89/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89f1/10369615/5a0aa3479a37/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89f1/10369615/b37ebb57dcf0/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89f1/10369615/a424f7939a94/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89f1/10369615/578964985c89/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89f1/10369615/5a0aa3479a37/gr4.jpg

相似文献

1
Immunosenescence, Immune Fitness and Vaccination Schedule in the Adult Respiratory Patient.成年呼吸系统疾病患者的免疫衰老、免疫健康与疫苗接种计划
Open Respir Arch. 2022 May 16;4(3):100181. doi: 10.1016/j.opresp.2022.100181. eCollection 2022 Jul-Sep.
2
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.20价肺炎球菌结合疫苗在阿根廷成年人中的成本效益
Infect Dis Ther. 2024 Jun;13(6):1235-1251. doi: 10.1007/s40121-024-00972-9. Epub 2024 May 3.
3
Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.15 价和 20 价肺炎球菌结合疫苗在日本老年人中的成本效益分析。
Vaccine. 2022 Nov 22;40(49):7057-7064. doi: 10.1016/j.vaccine.2022.10.010. Epub 2022 Oct 21.
4
Vaccines for the Elderly and Vaccination Programs in Europe and the United States.欧美针对老年人的疫苗及疫苗接种计划
Vaccines (Basel). 2024 May 22;12(6):566. doi: 10.3390/vaccines12060566.
5
Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.从德国社会角度分析PCV20预防儿童肺炎球菌疾病的成本效益
Infect Dis Ther. 2024 Jun;13(6):1333-1358. doi: 10.1007/s40121-024-00977-4. Epub 2024 May 11.
6
A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.一项评估20价肺炎球菌结合疫苗在65岁及以上有不同既往肺炎球菌疫苗接种史的成年人群中的安全性和免疫原性的试验。
Vaccine. 2021 Dec 17;39(51):7494-7502. doi: 10.1016/j.vaccine.2021.10.032. Epub 2021 Nov 25.
7
Real-World Coverage With Influenza, Pneumococcal, and Herpes Zoster Vaccines Among Patients With Rheumatic Diseases in a Nationwide Healthcare Plan.在一项全国性医疗保健计划中,风湿性疾病患者的流感、肺炎球菌和带状疱疹疫苗真实世界覆盖情况。
J Rheumatol. 2024 May 1;51(5):505-516. doi: 10.3899/jrheum.2023-0867.
8
[Alterations in responses to vaccines in older people].[老年人对疫苗反应的改变]
Rev Mal Respir. 2019 Nov;36(9):1047-1056. doi: 10.1016/j.rmr.2019.07.008. Epub 2019 Sep 12.
9
Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults.20 价肺炎球菌结合疫苗在比利时成年人中的成本-效用比,与不接种疫苗和推荐的替代疫苗相比。
Expert Rev Vaccines. 2023 Jan-Dec;22(1):1008-1021. doi: 10.1080/14760584.2023.2273892. Epub 2023 Nov 2.
10
The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus.疫苗接种在 COPD 中的作用:流感、SARS-CoV-2、肺炎球菌、百日咳、呼吸道合胞病毒和水痘带状疱疹病毒。
Eur Respir Rev. 2023 Sep 6;32(169). doi: 10.1183/16000617.0034-2023. Print 2023 Sep 30.

引用本文的文献

1
Age-related changes in the immune system and challenges for the development of age-specific vaccines.免疫系统的年龄相关变化以及针对特定年龄疫苗开发的挑战。
Ann Med. 2025 Dec;57(1):2477300. doi: 10.1080/07853890.2025.2477300. Epub 2025 Mar 20.
2
Prevalence of Respiratory Syncytial Virus Infection in Hospitalized COPD Patients in Spain Between 2018-2022.2018年至2022年西班牙住院慢性阻塞性肺疾病患者呼吸道合胞病毒感染的患病率
Diseases. 2025 Jan 20;13(1):23. doi: 10.3390/diseases13010023.
3
Respiratory syncytial virus: impact of the disease and preventive strategies in pregnant women and older adults: Number 6 - 2024.

本文引用的文献

1
[Future of vaccination against SARS-CoV-2 infection].[新型冠状病毒2感染疫苗接种的未来]
Open Respir Arch. 2021 Jun 29;3(3):100117. doi: 10.1016/j.opresp.2021.100117. eCollection 2021 Jul-Sep.
2
[SEPAR Recommendations for COVID-19 Vaccination in Patients With Respiratory Diseases].[呼吸系统疾病患者新冠病毒疫苗接种的SEPAR建议]
Open Respir Arch. 2021 Mar 22;3(2):100097. doi: 10.1016/j.opresp.2021.100097. eCollection 2021 Apr-Jun.
3
Pertussis Vaccine in COPD and Asthma: An Old Acquaintance Is Back.慢性阻塞性肺疾病和哮喘中的百日咳疫苗:一位老相识又回来了。
呼吸道合胞病毒:对孕妇和老年人疾病的影响及预防策略:2024年第6期
Rev Bras Ginecol Obstet. 2024 May 27;46. doi: 10.61622/rbgo/2024FPS06. eCollection 2024.
4
Aging-related biomarkers in testicular cancer survivors after different oncologic treatments.不同肿瘤治疗方法对睾丸癌幸存者与衰老相关的生物标志物的影响。
Cancer Med. 2024 Sep;13(18):e70200. doi: 10.1002/cam4.70200.
5
Factors related to first COVID-19 booster vaccine acceptance in Indonesia: A cross-sectional multi-center study.印度尼西亚首次接种新冠病毒加强针疫苗的相关因素:一项横断面多中心研究。
Narra J. 2024 Aug;4(2):e858. doi: 10.52225/narra.v4i2.858. Epub 2024 Jul 4.
6
GOLD 2024: a brief overview of key changes.《慢性阻塞性肺疾病全球倡议》2024版:关键变化简要概述
J Bras Pneumol. 2023 Dec 22;49(6):e20230369. doi: 10.36416/1806-3756/e20230369.
7
Targeted Application of Functional Foods as Immune Fitness Boosters in the Defense against Viral Infection.靶向应用功能性食品作为免疫增强剂,以抵御病毒感染。
Nutrients. 2023 Jul 28;15(15):3371. doi: 10.3390/nu15153371.
8
[Immunizing adult respiratory patients, shall we dance along?].为成年呼吸道疾病患者进行免疫接种,我们要一起行动吗?
Vacunas. 2023 Jun 10. doi: 10.1016/j.vacun.2023.04.005.
9
Inflammaging and Immunosenescence as Part of Skin Aging-A Narrative Review.炎症与免疫衰老及其在皮肤衰老中的作用——一篇综述。
Int J Mol Sci. 2023 Apr 24;24(9):7784. doi: 10.3390/ijms24097784.
10
Inhaled Colistimethate Sodium in the Management of Patients with Bronchiectasis Infected by : A Narrative Review of Current Evidence.吸入用硫酸多粘菌素甲磺酸钠在支气管扩张合并感染患者治疗中的应用:当前证据的叙述性综述
Infect Drug Resist. 2022 Dec 14;15:7271-7292. doi: 10.2147/IDR.S318173. eCollection 2022.
Open Respir Arch. 2021 Dec 21;4(1):100153. doi: 10.1016/j.opresp.2021.100153. eCollection 2022 Jan-Mar.
4
Whooping Cough: The Visible Enemy.百日咳:看得见的敌人。
Arch Bronconeumol. 2022 Apr;58(4):300-302. doi: 10.1016/j.arbres.2021.06.008. Epub 2021 Jun 24.
5
Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.《免疫功能低下的成年(≥19 岁)人群使用重组带状疱疹疫苗:免疫接种实践咨询委员会的建议-美国,2022 年》。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(3):80-84. doi: 10.15585/mmwr.mm7103a2.
6
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Medically Attended Lower Respiratory Tract Infection and Pneumonia Among Older Adults.13 价肺炎球菌结合疫苗在老年人中的有效性:针对医疗相关下呼吸道感染和肺炎。
Clin Infect Dis. 2022 Sep 14;75(5):832-841. doi: 10.1093/cid/ciab1051.
7
Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.关键性 3 期随机临床试验评估了 20 价肺炎球菌结合疫苗在 18 岁及以上成人中的安全性、耐受性和免疫原性。
Clin Infect Dis. 2022 Aug 31;75(3):390-398. doi: 10.1093/cid/ciab990.
8
A distinct association of inflammatory molecules with outcomes of COVID-19 in younger versus older adults.在年轻和老年 COVID-19 患者中,炎症分子与结局存在明显关联。
Clin Immunol. 2021 Nov;232:108857. doi: 10.1016/j.clim.2021.108857. Epub 2021 Sep 22.
9
Accelerated immunosenescence, oxidation and inflammation lead to a higher biological age in COPD patients.加速的免疫衰老、氧化和炎症导致 COPD 患者的生物年龄更高。
Exp Gerontol. 2021 Oct 15;154:111551. doi: 10.1016/j.exger.2021.111551. Epub 2021 Sep 13.
10
Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study.BNT162b2疫苗接种六个月后抗体反应的动态变化:一项纵向前瞻性研究。
Lancet Reg Health Eur. 2021 Nov;10:100208. doi: 10.1016/j.lanepe.2021.100208. Epub 2021 Sep 6.